Veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic stem cell transplantation: Middle East/North Africa regional consensus on prevention, diagnosis and management.

Pediatric Hematology/Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. Bone Marrow Transplant Program, King Hussein Cancer Center, Amman, Jordan. College of Medicine, Alfaisal University, Riyadh, Saudi Arabia. Pediatric Hematology/Oncology & HSCT, Department of Child Health, Sultan Qaboos University Hospital, Muscat, Oman. Leukemia, Bone Marrow Transplant Unit, King Abdulaziz Medical City-WR, National Guard Health Affairs, Jeddah, Saudi Arabia. Oncology Department, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. Department of Hematology and Cell Therapy, 1st November University Hospital, Ahmed Benbella University of Oran, Oran, Algeria. Department of Medicine, Makassed University Hospital, Beirut, Lebanon. Clinical Hematology, Faculty of Medicine and Pharmacy, CHU Mohammed VI, Marrakech, Morocco. Bone Marrow Transplant Unit, Kuwait Cancer Control Center, Shuwaikh, Kuwait. Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.

Bone marrow transplantation. 2017;(4):588-591

Abstract

Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) of the liver is a serious, early complication of haematopoietic stem cell transplantation (HSCT), severe and very severe forms of which are associated with a high mortality rate. A wide variety of patient, disease and treatment-related risk factors for VOD/SOS have been identified. Several bodies have published recommendations for the diagnosis, prevention and management of VOD/SOS following HSCT. A group of regional experts have developed a consensus statement on the diagnosis, prevention and management of VOD/SOS in the Middle East and North Africa region to help in the management of HSCT patients in the region. Risk factors of particular relevance in the region include iron overload in thalassaemia patients, some hereditary metabolic disorders due to consanguinity and infection with hepatitis virus B or C. Recommendations include diagnosis of VOD/SOS based on established clinical criteria, prophylaxis with defibrotide and/or ursodeoxycholic acid in patients at increased risk of VOD/SOS, and treatment with defibrotide for patients with severe/very severe VOD/SOS (and, if clinically indicated, in those with moderate or rapidly progressing VOD/SOS, as per the new European Society for Blood and Marrow Transplantation classification).

Methodological quality

Metadata